Merck tops quarterly estimates, hikes profit outlook as new Keytruda form shows strength

Source: CNBC Markets · 2026-10-29 11:24 UTC

Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.

Read the full story at CNBC Markets

Shared from the GodsView world desk: live wires next to a globe of flights, ships, fires, and quakes.

More from the world desk

DoorDash to acquire Instacart for $17 billion CNBC Markets
President of the European Central Bank Christine Lagarde to step down. Here's who is tipped to replace her CNBC Markets
Ameriprise Financial Non-GAAP EPS of $11.26 misses by $0.51, revenue of $5.19B beats by $110M Seeking Alpha
ING expects fee income to reach €5B in 2026 while outlining €300M lower 2027 costs Seeking Alpha
Tradeweb Markets declares $0.14 dividend Seeking Alpha
Microsoft Up, Google Down. A Tale of Two Hyperscalers. NYT Business

GodsView is a live globe of public flights, ships, wildfires, and earthquakes, plus a world news desk. Home · World desk · Globe · Blog · How to use · RSS · llms.txt